ProCE Banner Activity

Omicron Variant: Effects on Treatments for COVID-19

Podcast Episodes
Do COVID-19 treatments retain their efficacy against the SARS-CoV-2 omicron variant? Hear expert faculty discuss the use of direct-acting, small-molecule antiviral agents and monoclonal antibodies during the omicron era.

Released: January 25, 2022

Expiration: January 24, 2023

No longer available for credit.

Share

Faculty

Arthur Kim

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Arthur Kim, MD

Associate Professor of Medicine
Harvard Medical School
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD, has disclosed that he has served on the scientific advisory board for Kintor and served as a NIH-funded site-investigator for a prevention trial for casirivimab/imdevimab.